Reach Us +44-7482-864460
Donepezil for Lewy Body Constipation: A Six-Month Follow-up | OMICS International | Abstract
ISSN: 1747-0862

Journal of Molecular and Genetic Medicine
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.


Donepezil for Lewy Body Constipation: A Six-Month Follow-up

Lepkowsky CM*

Independent Practice, 1143 Deer Trail Lane, Solvang, California 93463, USA

*Corresponding Author:
Dr. Charles M. Lepkowsky
Independent Practice, 1143 Deer Trail Lane
Solvang, California 93463, USA
Tel: 805-688-1229
Fax: 805-686-9382
E-mail: [email protected]

Received Date: August 14, 2017; Accepted Date: August 29, 2017; Published Date: September 1, 2017

Citation: Lepkowsky CM (2017) Donepezil for Lewy Body Constipation: A Six-Month Follow-up. J Mol Genet Med 11:287. doi: 10.4172/1747-0862.1000287

Copyright: © 2017 Lepkowsky CM. This is an open-access article distributed under the terms of the creative commons attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


In a previous case study, four patients at different stages of Parkinson’s disease (PD) and Neurocognitive Disorder with Lewy Bodies (NCDLB) disease progression were treated with Donepezil, with the intention of mitigating Lewy body impairment of the cholinergic pathways in the myenteric plexus, increasing bowel motility, and reducing the symptom of constipation. In all four cases, the use of Donepezil was associated with significant reduction of the symptom of constipation. There was no exacerbation or instigation of other symptoms. The symptom status of the four patients was reviewed six months later. In none of the patients has there been exacerbation of the symptom of constipation, nor emergence of new symptoms. The findings suggest that Donepezil might have long-term efficacy for reducing constipation in patients with PD and NCDLB. Further research is recommended using larger numbers of subjects matched for diagnosis, age, gender, and other variables.